Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
vaccine in more than 30 countries, highlighting its LUNAR lipid nanoparticle delivery and repeat-dosing capabilities as key differentiators versus other mRNA developers. ARCT-810 has completed multiple Phase 1/2 trials in adults with favorable safety and biomarker signals, and the company is seeking FDA clarity on a pediatric (ages 0–6) approval path via Type C meetings and hopes to pursue a small single-arm pediatric study while targeting non-responders to competing gene therapies in adults. ARCT-032 will enter a 12-week inhaled cystic fibrosis study (~20 mostly Class I patients) at 10 mg/day using FEV and LCI endpoints, and Arcturus reports a cash runway into the second quarter of 2028 but needs strategic or non-dilutive funding to advance both lead programs through Phase 3. Interested in Arcturus Therapeutics Holdings Inc.? Here are five stocks we like better. Arcturus Therapeutics (NASDAQ:ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the compan
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- These Are the Only 3 Stocks That Cathie Wood Bought Last Week [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics (ARCT) was upgraded by B. Riley Financial, Inc. to "strong-buy".MarketBeat
- Arcturus Therapeutics (ARCT) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $22.00 price target on the stock.MarketBeat
- Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics: Downgrading To "Hold" As CF Program Shifts Population Focus [Seeking Alpha]Seeking Alpha
ARCT
Earnings
- 3/3/26 - Miss
ARCT
Sec Filings
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- ARCT's page on the SEC website